---
title: "Jefferies Keeps Their Buy Rating on Genmab A/S (0MGB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292404529.md"
description: "Jefferies analyst Benjamin Jackson maintained a Buy rating on Genmab A/S (0MGB) with a DKK2,800 price target on July 8. This contrasts with the stock's recent close of DKK1,892 and the broader market consensus of a Strong Buy with an average target of DKK2,407.14. Additionally, Barclays also upheld a Buy rating on Genmab with a DKK2,500 target."
datetime: "2026-07-12T12:15:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292404529.md)
  - [en](https://longbridge.com/en/news/292404529.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292404529.md)
---

# Jefferies Keeps Their Buy Rating on Genmab A/S (0MGB)

Jefferies analyst Benjamin Jackson CFA maintained a Buy rating on Genmab A/S on July 8 and set a price target of DKK2,800.00. The company’s shares closed last Friday at DKK1,892.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Jackson CFA is ranked #4459 out of 12332 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Genmab A/S with a DKK2,407.14 average price target, which is a 27.23% upside from current levels. In a report released on July 2, Barclays also maintained a Buy rating on the stock with a DKK2,500.00 price target.

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Genmab Updates Articles of Association, Expands Capital-Raising Flexibility](https://longbridge.com/en/news/295678408.md)
- [Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)](https://longbridge.com/en/news/295329030.md)
- [Capital Increase in Genmab as a Result of Employee Warrant Exercise](https://longbridge.com/en/news/295566458.md)
- [Weekly Recap: Epcoritamab‑lenalidomide PFS success and 2026 royalties rise](https://longbridge.com/en/news/295360680.md)
- [Jefferies Sticks to Its Buy Rating for Covista (CVSA)](https://longbridge.com/en/news/296118987.md)